7 results match your criteria: "and National Center of Competence in Research NCCR Kidney.CH.[Affiliation]"

The Ip6k1 and Ip6k2 Kinases Are Critical for Normal Renal Tubular Function.

J Am Soc Nephrol

April 2024

Switzerland and National Center of Competence in Research NCCR Kidney.CH, Institute of Physiology, University of Zurich, Zürich, Switzerland.

Significance Statement: Kidneys are gatekeepers of systemic inorganic phosphate balance because they control urinary phosphate excretion. In yeast and plants, inositol hexakisphosphate kinases (IP6Ks) are central to regulate phosphate metabolism, whereas their role in mammalian phosphate homeostasis is mostly unknown. We demonstrate in a renal cell line and in mice that Ip6k1 and Ip6k2 are critical for normal expression and function of the major renal Na + /Pi transporters NaPi-IIa and NaPi-IIc.

View Article and Find Full Text PDF

Background: Hyperphosphatemia is associated with increased mortality and cardiovascular morbidity of end-stage kidney failure (ESKF) patients. Managing serum phosphate in ESKF patients is challenging and mostly based on limiting intestinal phosphate absorption with low phosphate diets and phosphate binders (PB). In a multi-centric, double-blinded, placebo-controlled study cohort of maintenance hemodialysis patients with hyperphosphatemia, we demonstrated the efficacy of nicotinamide modified release (NAMR) formulation treatment in addition to standard PB therapy in decreasing serum phosphate.

View Article and Find Full Text PDF
Article Synopsis
  • FGF23 is a hormone from bone that regulates phosphate and vitamin D levels, and its excess leads to decreased expression of renal Dnase-1, which is linked to actin binding.
  • Research found that FGF23 suppresses Dnase-1 to help retrieve phosphate transporters from the kidney's surface by promoting actin growth, but Dnase1 expression varies in different dietary phosphate conditions.
  • The study concluded that Dnase-1 does not play a crucial role in how FGF23 inhibits phosphate reabsorption in the kidneys, demonstrating that the observed changes are not impactful on bone structure or function.
View Article and Find Full Text PDF

Background: Phosphate intake has increased in the last decades due to a higher consumption of processed foods. This higher intake is detrimental for patients with chronic kidney disease, increasing mortality and cardiovascular disease risk and accelerating kidney dysfunction. Whether a chronic high phosphate diet is also detrimental for the healthy population is still under debate.

View Article and Find Full Text PDF

Fibroblast growth factor 23 (FGF23) is a main regulator of mineral homeostasis. Low and high circulating FGF23 levels are associated with bone, renal, cardiovascular diseases, and increased mortality. Understanding the factors and signaling pathways affecting FGF23 levels is crucial for the management of these diseases and their complications.

View Article and Find Full Text PDF

Cognitive impairment is an increasingly recognized major cause of chronic disability and is commonly found in patients with chronic kidney disease (CKD). Knowledge of the relationship between kidney dysfunction and impaired cognition may improve our understanding of other forms of cognitive dysfunction. Patients with CKD are at an increased risk (compared with the general population) of both dementia and its prodrome, mild cognitive impairment (MCI), which are characterized by deficits in executive functions, memory and attention.

View Article and Find Full Text PDF

Low blood phosphate (Pi) reduces muscle function in hypophosphatemic disorders. Which Pi transporters are required and whether hormonal changes due to hypophosphatemia contribute to muscle function is unknown. To address these questions we generated a series of conditional knockout mice lacking one or both house-keeping Pi transporters Pit1 and Pit2 in skeletal muscle (sm), using the postnatally expressed human skeletal actin-cre.

View Article and Find Full Text PDF